Previous Close | 102.03 |
Open | 102.39 |
Bid | 106.47 x 800 |
Ask | 108.80 x 1300 |
Day's Range | 102.39 - 110.50 |
52 Week Range | 95.50 - 188.99 |
Volume | |
Avg. Volume | 685,714 |
Market Cap | 26.049B |
Beta (5Y Monthly) | 0.18 |
PE Ratio (TTM) | 5.34 |
EPS (TTM) | 20.34 |
Earnings Date | Nov 06, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jun 02, 2022 |
1y Target Est | 161.76 |
Subscribe to Yahoo Finance Plus to view Fair Value for BNTX
BioNTech (NASDAQ: BNTX) has turned in a dismal performance so far this year. The average analysts' price target reflects an upside potential of 56%. Granted, not every analyst is all that bullish about BioNTech.
The fight against COVID-19 isn't over yet, and the two companies remain very much in the battle.
Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX). CureVac previously failed to develop a successful COVID-19 vaccine during the pandemic, opting instead to focus on potential second-generation vaccines in partnership with GlaxoSmithKline. BioNTech, by contrast, generated tens of billions of dollars in annual revenue from its successful mRNA vaccines developed in partnership with Pfizer.